|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
H. Lee Moffitt Cancer Center and Research Institute National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00006368 |
Purpose
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I trial to study the effectiveness of yttrium Y 90 SMT 487 in treating patients who have refractory or recurrent cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain and Central Nervous System Tumors Breast Cancer Gastrointestinal Carcinoid Tumor Islet Cell Tumor Lung Cancer Lymphoma Melanoma (Skin) Neoplastic Syndrome |
Radiation: yttrium Y 90-edotreotide |
Phase I |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors |
| Study Start Date: | November 1999 |
OBJECTIVES: I. Determine the maximum tolerated dose of yttrium Y 90-SMT 487 in patients with recurrent malignant neoplasms that prove positive for somatostatin receptors. II. Determine the safety and lifetime serious adverse event profile of this regimen in these patients. II. Determine the antitumor effect and the effect of repeated administrations on the renal excretion pharmacokinetics of this regimen in these patients.
OUTLINE: This is a dose escalation, multicenter study. Patients undergo octreotide scintigraphy to determine the location of somatostatin receptors.
Patients then receive yttrium Y 90-SMT 487 IV over 15 minutes on day 1. Treatment continues every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are entered on course I (vertical dose escalation) and courses II, III, and IV (horizontal dose escalation). Cohorts receive escalating doses of yttrium Y 90-SMT 487 until the maximum tolerated dose (MTD) is determined. MTDs are determined for a single course and for 4 courses. The MTD is defined as the dose preceding that at which no more than 2 of 6 patients experience dose limiting toxicities. Results of course I determine the dosage of subsequent courses. Patients are evaluated on days 2 and 7, and at weeks 4 and 6, following each injection of yttrium Y 90-SMT 487. Patients are followed at 12 and 18 months and then annually thereafter.
PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed, progressive malignant neoplasm Clinical diagnosis of multiple endocrine neoplasia (MEN) types I and II allowed Tumors positive for somatostatin receptors by octreotide scintigraphy, such as: Pituitary Brain Endocrine pancreatic Lymphoma Carcinoid Melanoma Small cell lung Breast Disease not amenable to standard treatment OR Failed existing first and second line therapies (failed at least 1 regimen in the case of small cell lung cancer) Bone disease (no diffuse bone marrow involvement), pleural effusions, and ascites allowed
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Course I: Karnofsky 50-100% Courses II-IV: Karnofsky 30-100% Life expectancy: At least 6 months and no greater than 2.5 years (for course I only) Hematopoietic: Course I: Hemoglobin at least 8 g/dL WBC at least 3,500/mm3 Platelet count at least 100,000/mm3 Courses II-IV: WBC at least 3,000/mm3 Platelet count at least 75,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than 1.7 mg/dL OR Creatinine clearance at least 40 mL/min Cardiovascular: No history of congestive heart failure unless ejection fraction at least 40% Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 6 months after study No other concurrent malignancy except MEN I or II or squamous cell skin cancer No concurrent significant, uncontrolled, medical, psychiatric, or surgical condition that would preclude study (course 1)
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy Greater than 4 weeks since prior chemotherapy Endocrine therapy: At least 4 months since prior long acting somatostatin analogue Concurrent hormonal therapy (except somatostatin analogues) allowed if started at least 2 months previously Radiotherapy: Greater than 4 weeks since prior radiotherapy No prior radiotherapy to at least 25% of bone marrow Surgery: Greater than 4 weeks since prior surgery Other: Greater than 4 weeks since prior investigational drugs No other concurrent investigational drug therapy No other concurrent antineoplastic therapy Concurrent bisphosphonates allowed
Contacts and Locations| United States, Florida | |
| H. Lee Moffitt Cancer Center and Research Institute | |
| Tampa, Florida, United States, 33612-9497 | |
| Study Chair: | Larry K. Kvols, MD | H. Lee Moffitt Cancer Center and Research Institute |
More Information
| Study ID Numbers: | CDR0000068241, MCC-12275, MCC-IRB-5473, NOVARTIS-SMT-B151, NCI-G00-1857 |
| Study First Received: | October 4, 2000 |
| Last Updated: | February 6, 2009 |
| ClinicalTrials.gov Identifier: | NCT00006368 History of Changes |
| Health Authority: | United States: Federal Government |
|
stage IV adult Hodgkin lymphoma stage IV breast cancer recurrent breast cancer recurrent non-small cell lung cancer recurrent adult Hodgkin lymphoma extensive stage small cell lung cancer recurrent small cell lung cancer metastatic gastrointestinal carcinoid tumor recurrent gastrointestinal carcinoid tumor gastrinoma recurrent adult brain tumor insulinoma recurrent islet cell carcinoma ACTH-producing pituitary tumor prolactin-producing pituitary tumor |
growth hormone-producing pituitary tumor recurrent pituitary tumor TSH producing pituitary tumor nonfunctioning pituitary tumor adult brain stem glioma adult craniopharyngioma adult medulloblastoma adult meningioma adult glioblastoma stage IV melanoma recurrent melanoma stage IV non-small cell lung cancer WDHA syndrome somatostatinoma pancreatic polypeptide tumor |
|
Thoracic Neoplasms Glioblastoma Pancreatic Neoplasms Lymphoma, Mantle-Cell Pancreatic Polypeptide Octreotide Mantle Cell Lymphoma Central Nervous System Neoplasms Hormones Follicular Lymphoma Leukemia, Lymphocytic, Chronic, B-Cell Lung Neoplasms Zollinger-Ellison Syndrome Neuroepithelioma Glioma |
Hodgkin Disease Nervous System Neoplasms Breast Diseases Endocrine Gland Neoplasms Carcinoid Syndrome Lymphoma, Large B-Cell, Diffuse Immunoproliferative Disorders Digestive System Neoplasms Antineoplastic Agents, Hormonal Astrocytoma Carcinoma, Islet Cell Insulinoma Endocrine System Diseases Breast Neoplasms Adenoma, Islet Cell |
|
Thoracic Neoplasms Pancreatic Neoplasms Octreotide Central Nervous System Neoplasms Neoplasms by Site Pathologic Processes Lung Neoplasms Therapeutic Uses Breast Diseases Nervous System Neoplasms Endocrine Gland Neoplasms Immunoproliferative Disorders Digestive System Neoplasms Immune System Diseases Antineoplastic Agents, Hormonal |
Nervous System Diseases Breast Neoplasms Endocrine System Diseases Adenoma, Islet Cell Malignant Carcinoid Syndrome Carcinoma Neuroectodermal Tumors Neoplasms Lung Diseases Gastrointestinal Neoplasms Pancreatic Diseases Carcinoid Tumor Neoplasms, Glandular and Epithelial Gastrointestinal Diseases Antineoplastic Agents |
